Post-Dilation of Self-Expanding Valves: Frequency, Usefulness, and Risks

Post-Dilation of Self-Expanding ValvesThis study explores the impact of balloon post-dilation on studies conducted in the United States assessing the CoreValve self-expandable valve.

 

Procedural details of 3532 patients were examined to determine whether post-dilation was performed after valve implantation. Best practice guidelines recommend post-dilation to improve suboptimal outcomes, being the most frequent alternative for treating moderate or severe paravalvular insufficiency.

 

Post-dilation was performed in 782 patients (22%); the most common (58.1%) indication was greater than or equal to moderate paravalvular insufficiency. 

 

Predictors for the need for post-dilation were the following:

  • Baseline transvalvular gradients (p <0.001)
  • Higher baseline aortic insufficiency (p <0.001)
  • Larger annular diameter (p <0.001)
  • Lower device (p <0.001)

 

Post-dilation was significantly less frequent with the 26-mm devices (17.9%) compared to the 31-mm devices (38.1%).

 

Post-dilation effectively reduced moderate or severe aortic insufficiency by around 75.6% (from 58.1% to 14.2%).

 

Clinical outcomes at 30 days and 1 year were similar in both groups, except for a higher rate of acute kidney insufficiency in patients who underwent post-dilation (p = 0.026), which could be explained by the additional aortography necessary for control.

 

The rate of major adverse cardiovascular and cerebrovascular events was 9.3% in the post-dilation group and 7.5% for other patients (p = ns). There was no increase in neurological events.

 

Conclusion

Post-dilation was performed in 22% of patients receiving a CoreValve valve, most frequently due to a need to reduce the degree of residual paravalvular aortic insufficiency. Post-dilation effectively and immediately improved outcomes and was not associated with an increase in neurological events.

 

Original title: Balloon Post-Dilation Following Implantation of a Self-Expanding Transcatheter Aortic Valve Bioprosthesis.

Reference: J. Kevin Harrison et al. J Am Coll Cardiol Intv 2017;10:168-75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....